MedTrace Logo

Glargine U300 Hospital Trial

NCT03013985 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 247

Last updated 2020-05-07

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to find out if treatment with Glargine U300 when compared to Glargine U100 will result in similar sugar control in patients with Type 2 Diabetes (T2D), who are admitted to the hospital and then transition at home, after discharge from the hospital.

Conditions

Interventions

DRUG

Glargine U300

Glargine U300 is a new generation long-acting insulin.

DRUG

Glargine U100

Glargine U100 is a long-acting insulin.

DRUG

Glulisine Insulin

Glulisine is a mealtime insulin taken either 15 minutes before or 20 minutes after a meal.

Sponsors & Collaborators

  • Emory University

    lead OTHER

Principal Investigators

  • Guillermo Umpierrez, MD · Emory University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-17
Primary Completion
2019-03-22
Completion
2019-03-22
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03013985 on ClinicalTrials.gov